Braveheart Bio, Inc. (NASDAQ:BRVE) Short Interest Up ∞ in August

Braveheart Bio, Inc. (NASDAQ:BRVE) was the target of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 847,773 shares, a growth of ∞ from the July 30th total of 0 shares. Based on an average daily volume of 650,680 shares, the short-interest ratio is currently 1.3 days. Currently, 1.2% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th.

Braveheart Bio Price Performance

NASDAQ BRVE opened at $27.44 on Friday. Braveheart Bio has a 12 month low of $24.61 and a 12 month high of $32.00.

Insiders Place Their Bets

In related news, major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the transaction, the insider directly owned 10,232,420 shares of the company’s stock, valued at $184,183,560. This trade represents a 12.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth Opportunities F. Forbion bought 1,680,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $30,240,000.00. Following the completion of the transaction, the insider directly owned 10,185,478 shares in the company, valued at $183,338,604. This represents a 19.75% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 8,751,942 shares of company stock valued at $157,534,956 in the last 90 days.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.